SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

February 27, 2009 | 
1 min read
Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
Schizophrenia
Patient death prompts FDA pause on Newron’s Phase 3 schizophrenia study
April 30, 2026
 · 
2 min read
 · 
Tristan Manalac
A flower in the middle of the desert
Adcomms
FDA’s end to 9-month adcomm drought a ‘narrow restart’
April 30, 2026
 · 
7 min read
 · 
Tristan Manalac
Businessman pushing boulder uphill vector concept of Sisyphus. Symbol of hard work, futile effort, strength, struggle, challenge but also motivation and ambition. Eps10 vector illustration.
Adcomms
AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions
April 29, 2026
 · 
3 min read
 · 
Tristan Manalac
Cloud computing concept design.Cloud storage with data protected exchange Cloud computing, big data center, on dark blue background.Cloud Technology illustration concept.
Regulatory
Amgen, AstraZeneca join FDA effort harnessing cloud for real-time clinical trials
April 29, 2026
 · 
3 min read
 · 
Tristan Manalac